Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maribavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.41 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maribavir SCHEMBL13641210 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL4656419 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL4936315 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL1028527 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL13082009 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL13640277 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL7634766 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL18459197 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL18459376 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E | |
| Maribavir SCHEMBL7638886 | 1.00 | HDAC6 (1.00) | HDAC6SLC15A1HSPA5HSPA8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360414-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2020-11-19 | — | — | US | disclosed |
| US-10765692-B2 | Maribavir isomers, compositions, methods of making and methods of using | SHIRE VIROPHARMA INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200054658-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2020-02-20 | — | — | US | disclosed |
| US-10485813-B2 | Maribavir isomers, compositions, methods of making and methods of using | SHIRE VIROPHARMA INCORPORATED (US) | 2019-11-26 | — | — | US | disclosed |
| US-20170027974-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | SHIRE VIROPHARMA LLC | 2017-02-02 | — | — | US | disclosed |
| US-6455506-B1 | Lyxofuranosyl benzimidazoles as antiviral agents | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1000080-A1 | LYXOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | The Regents of The University of Michigan (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006424-A1 | LYXOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360414-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20200054658-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-20170027974-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-10765692-B2 | Maribavir isomers, compositions, methods of making and methods of using | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
| US-10485813-B2 | Maribavir isomers, compositions, methods of making and methods of using | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885SLC15A1 4512/4885HSPA5 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.